These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20962137)

  • 1. Development of a combined system for identification and classification of adverse drug reactions: Alerts Based on ADR Causality and Severity (ABACUS).
    Koh Y; Yap CW; Li SC
    J Am Med Inform Assoc; 2010; 17(6):720-2. PubMed ID: 20962137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system.
    Koh Y; Yap CW; Li SC
    Int J Med Inform; 2008 Jun; 77(6):421-30. PubMed ID: 17921048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
    Motola D; Vargiu A; Leone R; Conforti A; Moretti U; Vaccheri A; Velo G; Montanaro N
    Drug Saf; 2008; 31(7):609-16. PubMed ID: 18558794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of primary care prescribing rates for new drugs on spontaneous reporting of adverse drug reactions.
    Clark RC; Maxwell SR; Kerr S; Cuthbert M; Buchanan D; Steinke D; Webb DJ; Bateman ND
    Drug Saf; 2007; 30(4):357-66. PubMed ID: 17408312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".
    Luepker RV
    Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016
    [No Abstract]   [Full Text] [Related]  

  • 6. Bringing the FDA's Information to Market.
    Woloshin S; Schwartz LM
    Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960
    [No Abstract]   [Full Text] [Related]  

  • 7. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England.
    Layton D; Marshall V; Boshier A; Friedmann P; Shakir SA
    Drug Saf; 2006; 29(8):687-96. PubMed ID: 16872242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective analysis of VIOXX in Australia: using clinical trial data and linked administrative health data to predict patient groups at risk of an adverse drug event.
    Whitstock MT; Pearce CM; Ridout SC; Eckermann EJ
    Aust N Z J Public Health; 2010 Aug; 34(4):431-2. PubMed ID: 20649787
    [No Abstract]   [Full Text] [Related]  

  • 9. Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?
    Sommet A; Grolleau S; Bagheri H; Lapeyre-Mestre M; Montastruc JL;
    Eur J Clin Pharmacol; 2008 Aug; 64(8):829-34. PubMed ID: 18509626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Vioxx fallout.
    Palmer K
    Minn Med; 2005 Mar; 88(3):26-30. PubMed ID: 15852592
    [No Abstract]   [Full Text] [Related]  

  • 11. A tailor-made approach for causality assessment for ADR reports on drugs and vaccines.
    Oosterhuis I; Zweers P; Rümke H; Muller-Hansma A; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):544-550. PubMed ID: 30168222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular adverse effects associated with cyclooxygenase-2 inhibitors.
    Fraunfelder FW; Solomon J; Mehelas TJ
    Arch Ophthalmol; 2006 Feb; 124(2):277-9. PubMed ID: 16476901
    [No Abstract]   [Full Text] [Related]  

  • 13. [Principle of adverse drug reaction causality judgement and interpretation of causality assessment method both in China and abroad].
    Wei X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2012 Sep; 37(18):2744-7. PubMed ID: 23285925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causality assessment of adverse drug reaction reports using an expert-defined Bayesian network.
    Rodrigues PP; Ferreira-Santos D; Silva A; Polónia J; Ribeiro-Vaz I
    Artif Intell Med; 2018 Sep; 91():12-22. PubMed ID: 30077492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 inhibitors and the heart: putting risk in perspective.
    Bobadilla RV; Barnett EM; Randels CL
    Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool.
    Bracken LE; Nunn AJ; Kirkham JJ; Peak M; Arnott J; Smyth RL; Pirmohamed M; Turner MA
    PLoS One; 2017; 12(1):e0169393. PubMed ID: 28046035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bayesian generating function approach to adverse drug reaction screening.
    Northardt T
    PLoS One; 2024; 19(1):e0297189. PubMed ID: 38241386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
    Durrieu G; Olivier P; Montastruc JL;
    Eur J Clin Pharmacol; 2005 Sep; 61(8):611-4. PubMed ID: 16133552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study on the Classification, Causality, Preventability and Severity of Adverse Drug Reaction Using Spontaneous Reporting System in Hospitalized Patients.
    Sundaran S; Udayan A; Hareendranath K; Eliyas B; Ganesan B; Hassan A; Subash R; Palakkal V; Salahudeen MS
    Pharmacy (Basel); 2018 Sep; 6(4):. PubMed ID: 30274320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.